Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SMARCB1 regulates the hypoxic stress response in sickle cell trait.
Soeung M, Perelli L, Chen Z, Dondossola E, Ho IL, Carbone F, Zhang L, Khan H, Le CN, Zhu C, Peoples MD, Feng N, Jiang S, Zacharias NM, Minelli R, Shapiro DD, Deem AK, Gao S, Cheng EH, Lucchetti D, Walker CL, Carugo A, Giuliani V, Heffernan TP, Viale A, Tannir NM, Draetta GF, Msaouel P, Genovese G. Soeung M, et al. Among authors: cheng eh. Proc Natl Acad Sci U S A. 2023 May 23;120(21):e2209639120. doi: 10.1073/pnas.2209639120. Epub 2023 May 15. Proc Natl Acad Sci U S A. 2023. PMID: 37186844 Free PMC article.
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
Shapiro DD, Zacharias NM, Tripathi DN, Karki M, Bertocchio JP, Soeung M, He R, Westerman ME, Gao J, Rao P, Lam TNA, Jonasch E, Perelli L, Cheng EH, Carugo A, Heffernan TP, Walker CL, Genovese G, Tannir NM, Karam JA, Msaouel P. Shapiro DD, et al. Among authors: cheng eh. Clin Transl Med. 2023 May;13(5):e1267. doi: 10.1002/ctm2.1267. Clin Transl Med. 2023. PMID: 37226898 Free PMC article.
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
Elkrief A, Odintsov I, Markov V, Caeser R, Sobczuk P, Tischfield SE, Bhanot U, Vanderbilt CM, Cheng EH, Drilon A, Riely GJ, Lockwood WW, de Stanchina E, Tirunagaru VG, Doebele RC, Quintanal-Villalonga Á, Rudin CM, Somwar R, Ladanyi M. Elkrief A, et al. Among authors: cheng eh. J Thorac Oncol. 2023 Sep;18(9):1165-1183. doi: 10.1016/j.jtho.2023.05.007. Epub 2023 May 13. J Thorac Oncol. 2023. PMID: 37182602
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I, Odintsov I, Ishida K, Lui AJW, Kato M, Suzuki T, Zhang T, Wakayama K, Kurth RI, Cheng R, Fujita H, Delasos L, Vojnic M, Khodos I, Yamada Y, Ishizawa K, Mattar MS, Funabashi K, Chang Q, Ohkubo S, Yano W, Terada R, Giuliano C, Lu YC, Bonifacio A, Kunte S, Davare MA, Cheng EH, de Stanchina E, Lovati E, Iwasawa Y, Ladanyi M, Somwar R. Miyazaki I, et al. Among authors: cheng eh. Nat Cancer. 2023 Oct;4(10):1526. doi: 10.1038/s43018-023-00663-3. Nat Cancer. 2023. PMID: 37814012 Free PMC article. No abstract available.
155 results